{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:58:26Z","timestamp":1774292306547,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Complementary Therapies in Medicine"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ctim.2020.102481","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T12:25:35Z","timestamp":1591705535000},"page":"102481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis"],"prefix":"10.1016","volume":"52","author":[{"given":"Deepa","family":"Manwani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Kyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Amatuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillel W.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Carullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Davila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Ann","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S.","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctim.2020.102481_bib0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"10.1016\/j.ctim.2020.102481_bib0010","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ctim.2020.102481_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00062752-200203000-00003","article-title":"Sickle cell vaso-occlusion: Multistep and multicellular paradigm","volume":"9","author":"Frenette","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"10.1016\/j.ctim.2020.102481_bib0020","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.052522799","article-title":"Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm","volume":"99","author":"Turhan","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.ctim.2020.102481_bib0025","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2003-07-2209","article-title":"Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes","volume":"103","author":"Turhan","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctim.2020.102481_bib0030","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","article-title":"Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion","volume":"111","author":"Chang","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctim.2020.102481_bib0035","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.23956","article-title":"Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain crisis","volume":"90","author":"Manwani","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ctim.2020.102481_bib0040","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1096-8652(200102)66:2<151::AID-AJH1035>3.0.CO;2-Q","article-title":"Intravenous gammglobulin-associated acute renal failure","volume":"66","author":"Gupta","year":"2001","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ctim.2020.102481_bib0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5414\/CN106824","article-title":"Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004 - 2009","volume":"76","author":"Lin","year":"2011","journal-title":"Clin Nephrol"},{"issue":"4","key":"10.1016\/j.ctim.2020.102481_bib0050","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nm.1939","article-title":"Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury","volume":"15","author":"Hidalgo","year":"2009","journal-title":"Nat Med"},{"issue":"7570","key":"10.1016\/j.ctim.2020.102481_bib0055","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature15367","article-title":"Neutrophil ageing is regulated by the microbiome","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctim.2020.102481_bib0060","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.3324\/haematol.2018.199414","article-title":"Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results","volume":"103","author":"Boulad","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ctim.2020.102481_bib0065","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctim.2020.102481_bib0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.seminhematol.2018.04.007","article-title":"Novel sickle cell disease therapies: Targeting pathways downstream of sickling","volume":"55","author":"Morrone","year":"2018","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.ctim.2020.102481_bib0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/asheducation-2018.1.493","article-title":"New insights into the pathophysiology and development of novel therapies for sickle cell disease","volume":"2018","author":"Moerdler","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.ctim.2020.102481_bib0080","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease","volume":"104","author":"Carden","year":"2019","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.ctim.2020.102481_bib0085","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease","volume":"1","author":"Field","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctim.2020.102481_bib0090","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctim.2020.102481_bib0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2005.01.011","article-title":"Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17","volume":"22","author":"Stark","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ctim.2020.102481_bib0100","first-page":"110","article-title":"Bone marrow neutrophil aging in sickle cell disease mice is associated with impaired osteoblast functions","volume":"16","author":"Rana","year":"2018","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.ctim.2020.102481_bib0105","series-title":"Aged neutrophils in sickle cell disease impede ischemic repair","author":"Derick Okwan-Duodu","year":"2018"},{"key":"10.1016\/j.ctim.2020.102481_bib0110","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25637","article-title":"Rifaximin for sickle cell disease","author":"Lim","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ctim.2020.102481_bib0115","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1002\/ajh.25467","article-title":"Effects of rifaximin on circulating aged neutrophils in sickle cell disease","volume":"94","author":"Dutta","year":"2019","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.ctim.2020.102481_bib0120","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood-2017-04-780635","article-title":"Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion","volume":"130","author":"Carden","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctim.2020.102481_bib0125","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12353","article-title":"Normal saline is associated with increased sickle red cell stiffness and prolonged transit times in a microfluidic model of the capillary system","volume":"24","author":"Carden","year":"2017","journal-title":"Microcirculation"},{"issue":"1","key":"10.1016\/j.ctim.2020.102481_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26742","article-title":"Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: A single institution experience","volume":"65","author":"Carden","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.ctim.2020.102481_bib0135","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ajh.25471","article-title":"Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain","volume":"94","author":"Carden","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Complementary Therapies in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229919320606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229919320606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:13:23Z","timestamp":1760807603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0965229919320606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":27,"alternative-id":["S0965229919320606"],"URL":"https:\/\/doi.org\/10.1016\/j.ctim.2020.102481","relation":{},"ISSN":["0965-2299"],"issn-type":[{"value":"0965-2299","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized phase 2 trial of Intravenous Gamma Globulin (IVIG) for the treatment of acute vaso-occlusive crisis in patients with sickle cell disease: Lessons learned from the midpoint analysis","name":"articletitle","label":"Article Title"},{"value":"Complementary Therapies in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctim.2020.102481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102481"}}